The doses that appear in the CJC-1295 literature.

The short version

The doses that appear in the published CJC-1295 literature are subcutaneous injections in a narrow range: the Teichman 2006 Phase 1 study used 30, 60, 125, and 250 micrograms per kilogram in healthy adults, and a mouse study used 2 micrograms per injection. No efficacy dose-response curve was published for humans, because the Phase 2 trial that would have generated one was terminated before it read out. The long-acting DAC form has a measured plasma half-life of five to eight days; the short-acting no-DAC form clears in roughly 30 minutes. This page describes what appeared in the published research. It does not recommend doses to any person.

The Phase 1 human dose cohorts

Teichman and colleagues, 2006, examined single subcutaneous injections of CJC-1295 in healthy adults aged 21 to 61 at four dose levels — 30, 60, 125, and 250 micrograms per kilogram of body weight ^[2]. Separate cohorts received multiple injections on weekly or biweekly schedules across the two trials, which ran for 28 and 49 days respectively.

The published pharmacodynamic responses were dose-ordered. Growth hormone rose two- to ten-fold above baseline, with the larger end of that range observed at higher doses. IGF-1 rose 1.5- to three-fold. The investigators noted that the compound was 'safe and relatively well tolerated, particularly at doses of 30 or 60 micrograms per kilogram,' suggesting those lower doses provided the cleanest therapeutic-index signal in the study.

No cumulative-dose ceiling, no maintenance-dose recommendation, and no body-composition outcome was published. The Teichman paper is a PK/PD/safety paper, not an efficacy paper.

The terminated Phase 2 regimen

The Phase 2 trial in HIV-associated visceral obesity (NCT00267527) used weekly subcutaneous injections ^[3]. The specific micrograms-per-kilogram regimen used in the trial was not published in the peer-reviewed literature before the program was terminated in October 2006. The participant who experienced the fatal coronary event had received eleven weekly doses at the time of the event; the independent review judged the event unrelated to study drug.

Because no efficacy data from this trial were published, there is no body-composition dose-response curve in the human CJC-1295 literature. Inferences about chronic-use dose-response in adults must come from the related GHRH analog tesamorelin (which has an FDA label dose of 2 mg subcutaneous daily for HIV-associated lipodystrophy) or from mechanistic reasoning, not from a published CJC-1295 trial.

The mouse rescue dose

Alba and colleagues, 2006, used 2 micrograms per injection in GHRH-knockout mice administered at 24-, 48-, or 72-hour intervals for five weeks ^[4]. In a 25-gram juvenile mouse this works out to approximately 80 micrograms per kilogram per dose — broadly comparable on a μg/kg basis to the lower end of the Teichman human cohorts.

Once-daily dosing restored normal body weight and length; every-other-day and every-third-day dosing produced partial rescue. The Alba protocol is the cleanest dose-frequency dataset in the CJC-1295 literature, but it is a developmental-growth study in juvenile knockout mice and does not generalize directly to adult human pharmacology.

Route of administration

Every published in-vivo CJC-1295 study used the subcutaneous route. The albumin bioconjugation reaction depends on access to circulating serum albumin, which subcutaneous depot delivery provides slowly and reliably. Intravenous administration has been used in mechanistic studies of related native and analog GHRH peptides but does not appear in the published CJC-1295 development record.

Oral administration has not been studied in published CJC-1295 work and is not pharmacologically plausible — the peptide would be degraded by gastric proteases before reaching circulation. Intranasal and transdermal routes have similarly not been reported in peer-reviewed CJC-1295 literature.

Half-life and dose interval

The DAC variant's measured plasma half-life in healthy adults is 5.8 to 8.1 days ^[2]. That figure is the primary justification for the once-weekly dosing schedule used in the Phase 2 program: at weekly intervals, sequential doses produce cumulative IGF-1 elevation rather than discrete pulses, consistent with the observation that multiple-dose IGF-1 levels remained above baseline for up to 28 days.

The non-DAC backbone — modified GRF(1-29) — has a plasma half-life of approximately 30 minutes ^[1]. That short half-life is why the non-DAC variant is sometimes discussed in the research-chemical community as 'closer to physiological pulsatility' — a single dose stimulates one GH pulse and clears. The two variants are pharmacokinetically distinct and should not be discussed interchangeably.

Stability and storage in research conditions

Reconstituted CJC-1295 (either variant) is typically described in published methods and supplier protocols as stable when refrigerated short-term and frozen for longer-term storage. Repeated freeze-thaw cycles and exposure to elevated temperatures degrade activity. The DAC variant's bioactivity depends specifically on intact reactive maleimide chemistry until injection; once injected and albumin-bound, the bioconjugate is stable in circulation. None of these stability parameters appear in the peer-reviewed clinical literature in quantitative form — they come from preclinical method descriptions and product-information sheets, which is worth noting honestly.

What this section does not say

This page describes the doses that appear in the published CJC-1295 research literature so that any claim a reader encounters can be traced back to its source. It does not recommend a dose for any human research subject, athlete, or patient. CJC-1295 is not approved by the FDA for any indication, has not been accessible through 503A compounding since 2023, and is prohibited by WADA at all times for tested athletes ^[7][9].